Jinan Youlyy Industrial Co., Ltd.

The core supplier in pharmaceutical packagings

Home > News > Content
Pharmaceutical Industry In China
- Aug 04, 2017 -

The pharmaceutical industry is one of the leading industries in the People's Republic of China, And Youlyy Industrial Co., Ltd as a leading Chinese manufacturer of pharmceautical packaging company long time supply the top quality products(including aluminum cap, aluminum-plastic cap, glass vial, rubber stopper, glass ampoule, glass test tube, prefilled syringe, infusion bag etc) with the competitive price.

China accounts for 20% of the world’s population but only 1.5% of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.

The domestic pharmaceutical market is highly fragmented and inefficient. China, as of 2007, has around 3,000 to 6,000 domestic pharmaceutical manufacturers and around 14,000 domestic pharmaceutical distributors. The most often-cited adverse factors in the marketplace include a lack of protection of intellectual property rights, a lack of visibility for drug approval procedures, a lack of effective governmental oversight, poor corporate support for drug research, and differences in the treatment in China that are accorded to local and foreign firms.Nevertheless, China is reportedly expected to become the third-largest pharmaceuticals market in the world by 2011.

Research and development are increasing, with Shanghai becoming one of the most important global drug research centers. Most notably, Novartis is expected to establish a large Research and development base in Shanghai that will be a pillar of its drug development.

China's thousands of domestic companies account for 70% of the market, the top 10 companies about 20%, according to Business China. In contrast, the top 10 companies in most developed countries control about half the market. Since June 30, 2004, the State Food and Drug Administration (SFDA) has been closing down manufacturers that do not meet the new GMP standards. Foreign players account for 10% to 20% of overall sales, depending on the types of medicines and ventures included in the count. However, sales at the top-tier Chinese companies are growing faster than at Western ones.